Abstract
Inhibition of renal glucose transport, leading to induction of glycosuria is a therapeutic approach, which dates back to the early 80 the last century. Only in recent years in developing and exploring new selective inhibitors of glucose transporter SGLT2 a renaissance of this method of treatment.
Use of glycosuria in diabetes through inhibition of SGLT2 transporters (sodium glucose co-transporter) is a completely new approach to treat type 2 diabetes type. Attraction of new pharmacological group glucuretics gliflosine or using this mechanism lies in the simplicity and versatility.
Treatment is effective regardless of the underlying cause of hyperglycemia, ie regardless of the degree of insulin resistance and insulin secretion disorders. The article presents a summary of the physiology and pathophysiology of renal glucose transport, an overview of SGLT2 inhibitors developed and the results of previously published experimental and clinical studies.